Genetic variants of antioxidant and xenobiotic metabolizing enzymes and their association with prostate cancer: A meta-analysis and functional in silico analysis

• Published in: The Science of the total environment 2023-11, Vol.898, p.165530-165530, Article 165530
• Main Authors: Álvarez-González, Beatriz, Porras-Quesada, Patricia, Arenas-Rodríguez, Verónica, Tamayo-Gómez, Alba, Vázquez-Alonso, Fernando, Martínez-González, Luis Javier, Hernández, Antonio F., Álvarez-Cubero, María Jesús
• Format: Article
• Language: English
• Subjects: Antioxidant enzymes; antioxidants; carcinogenesis; computer simulation; DNA repair; environment; Genetic polymorphism; genotype; Meta-analysis; oxidative stress; Prostate cancer; prostatic neoplasms; risk; Xenobiotic metabolizing enzymes; xenobiotics
• ISSN: 0048-9697; 1879-1026
• DOI: 10.1016/j.scitotenv.2023.165530

The development and progression of prostate cancer (PCa) depends on complex interactions between genetic, environmental and dietary factors that modulate the carcinogenesis process. Interactions between chemical exposures and genetic polymorphisms in genes encoding xenobiotic metabolizing enzymes (XME), antioxidant enzymes and DNA repair enzymes have been reported as the main drivers of cancer. Thus, a better understanding of the causal risk factors for PCa will provide avenues to identify men at increased risk and will contribute to develop effective detection and prevention methods. We performed a meta-analysis on 17,518 cases and 42,507 controls obtained from 42 studies to determine whether seven SNPs and one CNV pertaining to oxidative stress, xenobiotic detoxification and DNA repair enzymes are associated with the risk of PCa (GPX1 (rs1050450), XRCC1 (rs25487), PON1 (rs662), SOD2 (rs4880), CAT (rs1001179), GSTP1 (rs1695) and CNV GSTM1). A significant increased risk of PCa was found for SOD2 (rs4880) ORGG+GA vs. AA 1.08; 95%CI 1.01–1.15, CAT (rs1001179) ORTT vs. TC+CC 1.39; 95%CI 1.17–1.66, PON1 (rs662) ORCT vs. CC+TT 1.17; 95%CI 1.01–1.35, GSTP1 (rs1695) ORGG vs. GA+AA 1.20; 95%CI 1.05–1.38 and GSTM1 (dual null vs. functional genotype) ORN vs. NN1+NN2 1.34; 95%CI 1.10–1.64. The meta-analysis showed that the CNV GSTM1, and the SNPs GSTP1 (rs1695) and CAT (rs1001179) are strongly associated with a greater risk of PCa and, to a lesser extent, the genetic variants SOD2 (rs4880) and PON1 (rs662). Although several antioxidant enzymes and XME play an important role in the PCa development, other risk factors such as chemical exposures should also be considered to gain insight on PCa risk. The functional in silico analysis showed that the genetic variants studied had no clinical implication regarding malignancy, except for GPX1 (rs1050450) SNP. Graphical abstract showing enzymes and receptors involved in xenobiotic detoxification, oxidative stress, estrogen signaling and DNA repair for which gene variants have been considered as biomarkers of susceptibility to prostate cancer. [Display omitted] •A meta-analysis on seven SNPs and one CNV and prostate cancer (PCa) was performed.•Genes pertained to oxidative stress, xenobiotic detoxication and DNA repair enzymes.•17,518 PCa cases and 42,507 controls were selected from 43 studies.•Genetic variants of GSTM1, GSTP1, CAT, SOD2 and PON1 increased the risk of PCa.•Genetic variants had no clinical implication regarding